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Abstract 
Introduction: Chemotherapy for primary central nervous system lymphoma (PCNSL) is based on 
methotrexate (MTX), which interferes with both nucleic acid synthesis and methionine 
metabolism. We have reported previously that genetic variants with influence on methionine 
metabolism are associated with MTX side effects, i.e. the occurrence of white matter lesions as a 
sign of MTX neurotoxicity. Here we investigated whether such variants are associated with 
MTX efficacy in terms of overall survival in MTX-treated PCNSL patients.  
Methods: We analyzed seven genetic variants influencing methionine metabolism in 68 PCNSL 
patients treated with systemic and facultative intraventricular MTX-based polychemotherapy 
(Bonn protocol).  
Results: Median age at diagnosis was 59 years (range: 28-77), 32 patients were female. Younger 
age (Wald = 8.9; p = 0.003) and the wild-type C (CC) allele of the genotype transcobalamin c. 
776C>G (Wald = 6.7; p = 0.010) were associated with longer overall survival in a multivariate 
COX regression analysis.  
Conclusion: This observation suggests that the missense variant transcobalamin c. 776C>G 
influences both neurotoxicity and efficacy of MTX in the Bonn PCNSL protocol.  
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Introduction 
Primary central nervous system lymphomas (PCNSL) represent approximately 2.4% of all 
primary brain tumors in the United States (Central Brain Tumor Registry of the United States, 
2004-2007). Untreated PCNSL has a poor prognosis of a median survival of only a few weeks. 
Treatment protocols include chemotherapies and brain irradiation. All first-line chemotherapy 
protocols in PCNSL are based on high-dose methotrexate (MTX), a competitive inhibitor of 
dihydrofolate reductase (DHFR), which synthesizes 5,10-methylenetetrahydrofolate (5,10-
MTHF; Figure 1 (Finkelstein, 1990). Thereby, MTX inhibits nucleic acid synthesis. However, 
5,10-MTHF is also used for the synthesis of 5-methyltetrahydrofolate (5-MTHF) by 5,10-
MTHF-reductase (MTHFR). Together with vitamin B12, which is transported by transcobalamin 
2 (Tc2), 5-MTHF serves as cofactor of methionine synthase, which synthesizes methionine from 
homocysteine. Methionine can be activated to S-adenosylmethionine, which acts a methyl group 
donor, e.g. for CNS myelination. The reduced folate carrier 1 (RFC1) is involved in the uptake of 
folate and MTX into the CNS.  
Variants of genes encoding these enzymes, transporter and carrier proteins of methionine 
metabolism are associated with MTX neurotoxicity as indicated by CNS white matter 
hyperintensities in T2 weighted magnetic resonance imaging (MRI) in PCNSL patients 
(Linnebank et al, 2007; Linnebank et al, 2009; Linnebank et al, 2005). In the present study we 
aimed at investigating whether these variants are also associated with the overall survival of 




We analyzed 68 consecutive PCNSL patients treated with the Bonn protocol with (n = 42) or 
without (n = 26) intraventricular therapy (Pels et al, 2009; Pels et al, 2003). Median age at 
diagnosis was 59 years (range: 28-77), 32 patients were female. Median Karnofsky score was 70 
(range: 50-100). Median time of follow-up was 44 months (range: 1-114). The MTX-based Bonn 
protocol with and without intraventricular treatment has been described in detail (Pels et al, 
2009; Pels et al, 2003). In brief, the protocol consisted of six chemotherapy cycles with 
intravenous high-dose MTX (cycles 1,2,4,5), high-dose cytarabine (ara-C; cycles 3,6) and vinca-
alkaloids, oral dexamethasone and (until 2002) intraventricular MTX, ara-C and prednisolone. 
Whereas 62 patients received the complete protocol, 6 patients terminated early because of 
progressive disease. In the entire population of patients intended to be treated, we analyzed seven 
genetic variants influencing methionine metabolism by PCR amplification of genomic DNA 
prepared from peripheral leucocytes and subsequent endonuclease restriction, where applicable. 
Amplicons were analyzed by agarose gel elecectrophoresis as published: CBS 844ins68, DHFR 
c.594+59del19bp, MTHFR c.677C>T, MTHFR c.1298A>C, MTR c.2756A>G, RFC1 c.80G>A, 
Tc2 c.776C>G (Linnebank et al, 2007; Linnebank et al, 2009; Linnebank et al, 2005). 
Multivariate COX regression analysis (forward stepwise; Wald) was used to analyze the 
association of age, gender, Karnofsky score before treatment, type of Bonn protocol (with or 
without intraventricular therapy) and the seven variants of methionine metabolism with overall 
survival as the primary parameter of interest. In addition, the association of the genetic variants 
with further dependent variables was tested in exploratory analyses, together with the same co-
variables as before: treatment response (complete remission, CR, including complete remission 
unconfirmed, Cru, versus incomplete response/ others; multinominal regression analysis), 
response duration (COX regression), time to treatment failure (COX regression), and Karnofsky 
performance score (ANOVA) (Pels et al, 2009; Pels et al, 2003). Overall survival was 
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determined from time of histological diagnosis to date of death. Response duration was 
calculated from the time when response was first documented to relapse. Time to treatment 
failure was calculated from initiation of treatment to date of disease progression, relapse, death 
or premature termination of therapy due to any cause (Pels et al, 2003). Response was 
categorized according to a consensus of the International PCNSL cooperative group (Abrey et al, 
2005). Median overall survival was not reached at the time of this analysis; thus, we provide 
mean values where applicable. Deviations of genotype distributions from the Hardy Weinberg 
equation were tested by a Chi
2
 goodness-of-fit test. Univariate Log Rank analyses with Kaplan 
Meier curves were used to illustrate data. ANOVA was used to exclude significant differences of 
age between groups defined by Tc2 genotypes. Threshold was defined with alpha < 0.05. All 
patients or their legal trustees gave informed written consent to this study, which was approved 
by the local ethics committee. 
 
Results 
Genotyping succeeded for all patients. No genotype distribution deviated from the Hardy-
Weinberg equation. In multivariate COX analysis of the intent-to-treat-population, younger age 
was significantly associated with longer survival (Wald = 6.4; p = 0.011), but not clearly with 
higher Karnofsky performance score before therapy (Wald = 2.7; p = 0.098). Gender showed no 
significant association in this population (Wald = 0.21; p= 0.649). In addition, the wild-type C 
allele of Tc2 c.776C>G was associated with overall survival suggesting a gene-dose effect (Table 
1; Figure 2). Of the group of patients with the CC genotype, two patients died due to tumour 
progression. Of the group with the CC genotype with CG genotype, four patients died to tumour 
progression, one patient due to therapy-associated toxicity, and three patients probably due 
tumour progression, which was not proved by imaging. Of the group with the GG genotype, five 
patients died due to tumour progression. Of those six patients who did not complete treatment 
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due to early progression, each two carried the genotypes CC, CG and GG not suggesting that the 
Tc2 genotype was associated with incomplete treatment.     
In explorative secondary analyses, patients with the wild-type CC genotype seemed had a longer 
response duration (median not yet reached; mean: 74±11 months) and a longer time to treatment 
failure (61±12 months) than the other patients (43±9 and 38±7, respectively; not significant). 
Further, 14 of the 20 patients (0.70) homozygous for the wild-type CC genotype of Tc2 
c.776C>G had a complete remission compared with only 24 of the 48 patients (0.50) with the 
mutant CG or GG genotypes, but this was not significant, either. In addition, the wild-type C 
allele was associated with a better Karnofsky performance score after treatment for trend (p = 
0.054; Table 2). None of the patients who completed therapy suffered from overt 
neurotoxicity. However, several patients developed white matter changes visible in T2 FLAIR 
MRI as published previously. If development of such white matter changes was set as 
covariable in the COX analysis, the association of Tc2 c.776C>G with overall survival was still 
significant (p=0.03), whereas the other genotypes still did not show significant associations 
(not shown). The patient groups defined by Tc2 genotypes did not differ in age, CC (56±11 
years), CG (58±12), GG (56±14; p=0.722). 
 
Discussion 
Current MTX-based treatment protocols for PCNSL achieve high response rates and clearly have 
improved prognosis. However, a substantial fraction of patients experience serious adverse 
events during treatment, have incomplete responses only or suffer from relapses. Individual 
factors like age and Karnofsky performance score prior to treatment are predictive concerning 
the clinical outcome (Abrey et al, 2006; Ferreri et al, 2003; Jahnke & Thiel, 2009). This was 
confirmed in our study (Karnofsky performance score: trend only) arguing for the 
representativity of the study population. Another predictive factor, i.e. early complete response to 
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initial treatment (Pels et al, 2010) was not analyzed in this study. The identification of additional 
factors like genetic variants may help to further improve individual prediction of outcome for 
different therapeutic options.  
 
In the present study, we report that the mutant G allele of Tc2 c.776C>G was associated with 
shorter overall survival of PCNSL patients treated with the high-dose MTX-based Bonn protocol 
(Table 1). We have reported previously that this mutant G allele is associated with MTX-
neurotoxicity as indicated by white matter changes detected in T2-weighted magnet resonance 
imaging MRI (Linnebank et al, 2009; Linnebank et al, 2005). Interestingly, in the present study, 
we also observed an association of this mutant variant with lower Karnofsky performance scores 
after therapy for trend as a further possible indicator of the relevance of this variant for MTX 
toxicity. Alternatively, the lower Karnofsky performance score in carriers of the G-allele may 
also be explained by reduced therapeutic efficacy of MTX as suggested by the data summarized 
in Table 2.  
 
Tc2 is the transporter protein of cobalamin (vitamin B12), which is necessary to remethylate 
methionine and S-adenosylmethionine from homocysteine. S-adenosylmethionine is needed to 
synthesize e.g. myelin basic protein, phospholipids and sphingomyelins. Such molecules are 
necessary for CNS integrity and myelination, and, accordingly, deficiency of S-
adenosylmethionine can cause demyelination of the central nervous system (Figure 1) (Surtees et 
al, 1991). The missense mutant G variant of Tc2 c.776C>G (p.P259R) lowers the affinity of Tc2 
to cobalamin and leads to reduced concentrations of blood Tc2-cobalamin complexes, e.g. 
reducing the biological availability of cobalamin for methionine and S-adenosylmethionine 
synthesis (von Castel-Dunwoody et al, 2005). This may explain why the mutant G-allele of Tc2 
c.776C>G is associated with progressive demyelination in patients with X-chromosomal 
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adrenoleukodystrophy and the occurrence of white matter T2 hyperintensities on brain MRI in 
PCNSL patients treated with the MTX-based Bonn protocol (Linnebank et al, 2009; Linnebank 
et al, 2005; Semmler et al, 2009). During MTX treatment, patients with one or two mutant G 
alleles and, as consequence, with a lower availability of cobalamin for 5-MTHF-dependent 
methionine synthesis will experience pronounced MTX-induced S-adenosylmethionine depletion 
leading to a higher risk of neurotoxicity and a lower consumption of 5,10-MTHF for 5-MTHF 
synthesis (Figure 1). In parallel, more 5,10-MTHF might be left for nucleic acid synthesis, 
possibly decreasing MTX efficacy as one possible explanation of an association with overall 
survival observed in this cohort (Figure 2c). In our study, additional explorative analyses, which 
were not powered to yield significant results with respect to the small subgroup sizes, suggested 
that the association of Tc2 c.776C>G with overall survival may be explained by both, a 
modification of instantaneous MTX treatment efficacy and toxicity. This is indicated by the post-
treatment Karnofsky performance score and by sustained treatment efficacy, as indicated by the 
time to relapse and time to treatment failure. As limitations, the results of our study remain to be 
retested in an independent population of PCNSL patients and, preferably, also other MTX-treated 
populations. We cannot exclude that other factors like differences in the MTX concentrations in 
the target tissue have confounded our findings. Additional mechanisms including an interaction 
between Tc2 c.776C>G and rescue with leucovorin (formyltetrahydrofolate), which is converted 
to 5,10-MTHF antagonizing MTX, may also be relevant, but were not analyzed in our study. 
Further, the biological consequences of Tc2 c.776C>G may be modified by vitamin B12 or folate 
plasma levels (Stanislawska-Sachadyn et al, 2010), which were not measured in our study 
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Figure 1 – Human methionine metabolism 
Methotrexate (MTX) inhibits dihydrofolate reductase (DHFR), which synthesizes 5,10-CH2-FH4 
from the folate pool in two subsequent steps. The reduced folate carrier 1 (RFC1) is involved in 
the uptake of 5,10-CH2-FH4 and MTX to tissues and organs including the central nervous 
system. 5,10-CH2-FH4 is needed for nucleic acid synthesis and, alternatively, can be reduced by 
methylenetetrahydrofolate reductase (MTHFR) to 5-methyltetrahydrofolate (5-CH3-FH4). 
Together with methylcobalamin, 5-CH3-FH4 is used by 5-methyltetrahydrofolate-homocysteine 
S-methyltransferase (MTR, also called methionine synthase) to synthesize methionine. 
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Transcobalamin 2 (Tc2) is the major transporter protein for cobalamin. Activated methionine (S-
adenosylmethionine, SAM) is the methyl group donor for numerous reactions. The degradation 
product of SAM is S-adenosylhomocysteine (SAH), which is hydrolyzed to homocysteine by 
SAH-hydrolase. Homocysteine can be transsulfurated to cystathionine by the vitamin B6-
dependent cystathionine beta-synthase (CBS), and subsequently, via the vitamin B6-dependent 


















Figure 2 – Age, Kanrofsky performance score, Tc2 c.776C>G, and overall survival  
Overall survival of patients grouped by a) age (<60 = black line, 60 years = broken line), b) 
Karnofsky performance score (< 70 = broken line,  70 = black line) and c) Tc2 c.776C>G 
genotype (CC = black line, CG = broken line, GG = grey line) is illustrated by Kaplan Meier 





Table 1: Variants and mean overall survival (months) 
Variant Genotype and overall survival COX-regression:  
Wald; p 
 
CBS844ins68 del/del (.82)  ins/del (.18) ins/ins (-)  
 81±7  56±9 not observed 1.1; 0.304 
DHFR 
c.594+59del19bp 
del/del (.20) ins/del (.50) ins/ins (.31)  
 87±13 78±10  60±9 2.0; 0.162 
MTHFR c.677C>T CC (.52) CT (.36) TT (.13)  
 76±10 64±8 101±12 1.0; 0.310 
MTHFR c.1298A>C AA (.53) AC (.37) CC (.10)  
 81±9 75±11 60±11 0.018; 0.892 
MTR c.2756A>G AA (.66) AG/GG (.34)   
 79±8 79±11 0.38; 0.537 
RFC1 c.80G>A GG (.31) AG (.42) AA (.26)  
 78±12 72±11 68±5 0.69; 0.408 
Tc2 c.776C>G CC (.34) CG (.44) GG (.23)  
 100±8 76±11 52±10 7.3; 0.007 
     
 
Median overall survival was not yet reached. Thus, mean overall survival in months ± 1 standard 
deviation is depicted. P-values refer to multivariate analysis with age and gender and Karnofsky 
performance score before therapy as co-variables. The GG genotype of MTR c.2756A>G was 
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only observed in two patients. Thus, for statistical analysis, GG was pooled with AG.  
 
Table 2: Transcobalamin c. 776C>G genotypes and mean Karnofsky scores 
TC2 CC CG GG ANOVA: F; p 
Karnofsky score 
before treatment 
77±12 71±18 70±17 0.62; 0.543 
Karnofsky score  
after treatment 
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